United Therapeutics Corporation is a biopharmaceutical company that develops treatments for pulmonary hypertension and other serious diseases, operating through two core segments: pharmaceutical therapies and organ manufacturing technologies. The company's primary revenue comes from a portfolio of treprostinil-based drugs in multiple formulations (inhaled, oral, and injected) for pulmonary arterial hypertension and related conditions, along with Unituxin for pediatric neuroblastoma; these products are distributed globally through specialty pharmaceutical partners to hospitals, specialty pharmacies, and directly to patients. The company also maintains a strategic pipeline in orphan disease indications and invests in xenotransplantation and regenerative medicine platforms aimed at addressing the long-term shortage of transplantable organs, positioning itself beyond traditional pharmaceutical commerce.